

Global Targeted Radionuclide Therapy Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/G559EDA6F8C6EN.html>

Date: October 2023

Pages: 118

Price: US\$ 4,480.00 (Single User License)

ID: G559EDA6F8C6EN

Abstracts

The global Targeted Radionuclide Therapy market size is expected to reach \$ 3154.4 million by 2029, rising at a market growth of 16.7% CAGR during the forecast period (2023-2029).

The key drivers of the radioimmunotherapy market is its potential to deliver highly targeted and precise treatment to cancer cells, sparing healthy tissues and reducing side effects compared to traditional radiation therapies. The ability of RIT to offer personalized treatment options based on specific cancer biomarkers further enhances its appeal in the field of precision medicine. However, the radioimmunotherapy market also faces challenges. One major challenge is the high cost associated with the development and production of radiopharmaceuticals, limiting access for some patients and healthcare systems. Additionally, navigating complex regulatory pathways for approval and reimbursement of RIT products can be time-consuming and resource-intensive for pharmaceutical companies. Furthermore, there may be limited awareness and acceptance of RIT among healthcare professionals and patients, leading to slower adoption rates and market penetration. Addressing these challenges requires continued research and investment in RIT technologies to improve efficacy and cost-effectiveness. Collaborations between pharmaceutical companies, research institutions, and healthcare organizations can facilitate knowledge-sharing and streamline the regulatory process.

Therapeutic Radioligands is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.

This report studies the global Targeted Radionuclide Therapy demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Targeted Radionuclide Therapy, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Targeted Radionuclide Therapy that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Targeted Radionuclide Therapy total market, 2018-2029, (USD Million)

Global Targeted Radionuclide Therapy total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Targeted Radionuclide Therapy total market, key domestic companies and share, (USD Million)

Global Targeted Radionuclide Therapy revenue by player and market share 2018-2023, (USD Million)

Global Targeted Radionuclide Therapy total market by Type, CAGR, 2018-2029, (USD Million)

Global Targeted Radionuclide Therapy total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Targeted Radionuclide Therapy market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences and Clarity Pharmaceuticals, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Targeted Radionuclide Therapy market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Targeted Radionuclide Therapy Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Targeted Radionuclide Therapy Market, Segmentation by Type

Beta-emitting

Targeted Alpha Therapy

Global Targeted Radionuclide Therapy Market, Segmentation by Application

Solid Tumor

Non Hodgkin Lymphoma

Companies Profiled:

Bayer

Novartis

Lantheus

Aurobindo Pharma

Mundipharma

China Isotope & Radiation

Curium Pharmaceuticals

Gilead Sciences

Clarity Pharmaceuticals

Curasight

Nordic Nanovector

Philogen

RadioMedix

Telix Pharmaceuticals

Orano Med

Actinium Pharmaceuticals

Y-mAbs Therapeutics

Fusion Pharmaceuticals

Key Questions Answered

1. How big is the global Targeted Radionuclide Therapy market?
2. What is the demand of the global Targeted Radionuclide Therapy market?
3. What is the year over year growth of the global Targeted Radionuclide Therapy market?
4. What is the total value of the global Targeted Radionuclide Therapy market?
5. Who are the major players in the global Targeted Radionuclide Therapy market?

Contents

1 SUPPLY SUMMARY

- 1.1 Targeted Radionuclide Therapy Introduction
- 1.2 World Targeted Radionuclide Therapy Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Targeted Radionuclide Therapy Total Market by Region (by Headquarter Location)
 - 1.3.1 World Targeted Radionuclide Therapy Market Size by Region (2018-2029), (by Headquarter Location)
 - 1.3.2 United States Targeted Radionuclide Therapy Market Size (2018-2029)
 - 1.3.3 China Targeted Radionuclide Therapy Market Size (2018-2029)
 - 1.3.4 Europe Targeted Radionuclide Therapy Market Size (2018-2029)
 - 1.3.5 Japan Targeted Radionuclide Therapy Market Size (2018-2029)
 - 1.3.6 South Korea Targeted Radionuclide Therapy Market Size (2018-2029)
 - 1.3.7 ASEAN Targeted Radionuclide Therapy Market Size (2018-2029)
 - 1.3.8 India Targeted Radionuclide Therapy Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Targeted Radionuclide Therapy Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Targeted Radionuclide Therapy Major Market Trends

2 DEMAND SUMMARY

- 2.1 World Targeted Radionuclide Therapy Consumption Value (2018-2029)
- 2.2 World Targeted Radionuclide Therapy Consumption Value by Region
 - 2.2.1 World Targeted Radionuclide Therapy Consumption Value by Region (2018-2023)
 - 2.2.2 World Targeted Radionuclide Therapy Consumption Value Forecast by Region (2024-2029)
- 2.3 United States Targeted Radionuclide Therapy Consumption Value (2018-2029)
- 2.4 China Targeted Radionuclide Therapy Consumption Value (2018-2029)
- 2.5 Europe Targeted Radionuclide Therapy Consumption Value (2018-2029)
- 2.6 Japan Targeted Radionuclide Therapy Consumption Value (2018-2029)
- 2.7 South Korea Targeted Radionuclide Therapy Consumption Value (2018-2029)
- 2.8 ASEAN Targeted Radionuclide Therapy Consumption Value (2018-2029)
- 2.9 India Targeted Radionuclide Therapy Consumption Value (2018-2029)

3 WORLD TARGETED RADIONUCLIDE THERAPY COMPANIES COMPETITIVE ANALYSIS

- 3.1 World Targeted Radionuclide Therapy Revenue by Player (2018-2023)
- 3.2 Industry Rank and Concentration Rate (CR)
 - 3.2.1 Global Targeted Radionuclide Therapy Industry Rank of Major Players
 - 3.2.2 Global Concentration Ratios (CR4) for Targeted Radionuclide Therapy in 2022
 - 3.2.3 Global Concentration Ratios (CR8) for Targeted Radionuclide Therapy in 2022
- 3.3 Targeted Radionuclide Therapy Company Evaluation Quadrant
- 3.4 Targeted Radionuclide Therapy Market: Overall Company Footprint Analysis
 - 3.4.1 Targeted Radionuclide Therapy Market: Region Footprint
 - 3.4.2 Targeted Radionuclide Therapy Market: Company Product Type Footprint
 - 3.4.3 Targeted Radionuclide Therapy Market: Company Product Application Footprint
- 3.5 Competitive Environment
 - 3.5.1 Historical Structure of the Industry
 - 3.5.2 Barriers of Market Entry
 - 3.5.3 Factors of Competition
- 3.6 Mergers, Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)

- 4.1 United States VS China: Targeted Radionuclide Therapy Revenue Comparison (by Headquarter Location)
 - 4.1.1 United States VS China: Targeted Radionuclide Therapy Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
 - 4.1.2 United States VS China: Targeted Radionuclide Therapy Revenue Market Share Comparison (2018 & 2022 & 2029)
- 4.2 United States Based Companies VS China Based Companies: Targeted Radionuclide Therapy Consumption Value Comparison
 - 4.2.1 United States VS China: Targeted Radionuclide Therapy Consumption Value Comparison (2018 & 2022 & 2029)
 - 4.2.2 United States VS China: Targeted Radionuclide Therapy Consumption Value Market Share Comparison (2018 & 2022 & 2029)
- 4.3 United States Based Targeted Radionuclide Therapy Companies and Market Share, 2018-2023
 - 4.3.1 United States Based Targeted Radionuclide Therapy Companies, Headquarters (States, Country)
 - 4.3.2 United States Based Companies Targeted Radionuclide Therapy Revenue,

(2018-2023)

4.4 China Based Companies Targeted Radionuclide Therapy Revenue and Market Share, 2018-2023

4.4.1 China Based Targeted Radionuclide Therapy Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies Targeted Radionuclide Therapy Revenue, (2018-2023)

4.5 Rest of World Based Targeted Radionuclide Therapy Companies and Market Share, 2018-2023

4.5.1 Rest of World Based Targeted Radionuclide Therapy Companies, Headquarters (States, Country)

4.5.2 Rest of World Based Companies Targeted Radionuclide Therapy Revenue, (2018-2023)

5 MARKET ANALYSIS BY TYPE

5.1 World Targeted Radionuclide Therapy Market Size Overview by Type: 2018 VS 2022 VS 2029

5.2 Segment Introduction by Type

5.2.1 Beta-emitting

5.2.2 Targeted Alpha Therapy

5.3 Market Segment by Type

5.3.1 World Targeted Radionuclide Therapy Market Size by Type (2018-2023)

5.3.2 World Targeted Radionuclide Therapy Market Size by Type (2024-2029)

5.3.3 World Targeted Radionuclide Therapy Market Size Market Share by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

6.1 World Targeted Radionuclide Therapy Market Size Overview by Application: 2018 VS 2022 VS 2029

6.2 Segment Introduction by Application

6.2.1 Solid Tumor

6.2.2 Non Hodgkin Lymphoma

6.3 Market Segment by Application

6.3.1 World Targeted Radionuclide Therapy Market Size by Application (2018-2023)

6.3.2 World Targeted Radionuclide Therapy Market Size by Application (2024-2029)

6.3.3 World Targeted Radionuclide Therapy Market Size by Application (2018-2029)

7 COMPANY PROFILES

7.1 Bayer

7.1.1 Bayer Details

7.1.2 Bayer Major Business

7.1.3 Bayer Targeted Radionuclide Therapy Product and Services

7.1.4 Bayer Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)

7.1.5 Bayer Recent Developments/Updates

7.1.6 Bayer Competitive Strengths & Weaknesses

7.2 Novartis

7.2.1 Novartis Details

7.2.2 Novartis Major Business

7.2.3 Novartis Targeted Radionuclide Therapy Product and Services

7.2.4 Novartis Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)

7.2.5 Novartis Recent Developments/Updates

7.2.6 Novartis Competitive Strengths & Weaknesses

7.3 Lantheus

7.3.1 Lantheus Details

7.3.2 Lantheus Major Business

7.3.3 Lantheus Targeted Radionuclide Therapy Product and Services

7.3.4 Lantheus Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)

7.3.5 Lantheus Recent Developments/Updates

7.3.6 Lantheus Competitive Strengths & Weaknesses

7.4 Aurobindo Pharma

7.4.1 Aurobindo Pharma Details

7.4.2 Aurobindo Pharma Major Business

7.4.3 Aurobindo Pharma Targeted Radionuclide Therapy Product and Services

7.4.4 Aurobindo Pharma Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)

7.4.5 Aurobindo Pharma Recent Developments/Updates

7.4.6 Aurobindo Pharma Competitive Strengths & Weaknesses

7.5 Mundipharma

7.5.1 Mundipharma Details

7.5.2 Mundipharma Major Business

7.5.3 Mundipharma Targeted Radionuclide Therapy Product and Services

7.5.4 Mundipharma Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)

- 7.5.5 Mundipharma Recent Developments/Updates
- 7.5.6 Mundipharma Competitive Strengths & Weaknesses
- 7.6 China Isotope & Radiation
 - 7.6.1 China Isotope & Radiation Details
 - 7.6.2 China Isotope & Radiation Major Business
 - 7.6.3 China Isotope & Radiation Targeted Radionuclide Therapy Product and Services
 - 7.6.4 China Isotope & Radiation Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
 - 7.6.5 China Isotope & Radiation Recent Developments/Updates
 - 7.6.6 China Isotope & Radiation Competitive Strengths & Weaknesses
- 7.7 Curium Pharmaceuticals
 - 7.7.1 Curium Pharmaceuticals Details
 - 7.7.2 Curium Pharmaceuticals Major Business
 - 7.7.3 Curium Pharmaceuticals Targeted Radionuclide Therapy Product and Services
 - 7.7.4 Curium Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
 - 7.7.5 Curium Pharmaceuticals Recent Developments/Updates
 - 7.7.6 Curium Pharmaceuticals Competitive Strengths & Weaknesses
- 7.8 Gilead Sciences
 - 7.8.1 Gilead Sciences Details
 - 7.8.2 Gilead Sciences Major Business
 - 7.8.3 Gilead Sciences Targeted Radionuclide Therapy Product and Services
 - 7.8.4 Gilead Sciences Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
 - 7.8.5 Gilead Sciences Recent Developments/Updates
 - 7.8.6 Gilead Sciences Competitive Strengths & Weaknesses
- 7.9 Clarity Pharmaceuticals
 - 7.9.1 Clarity Pharmaceuticals Details
 - 7.9.2 Clarity Pharmaceuticals Major Business
 - 7.9.3 Clarity Pharmaceuticals Targeted Radionuclide Therapy Product and Services
 - 7.9.4 Clarity Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
 - 7.9.5 Clarity Pharmaceuticals Recent Developments/Updates
 - 7.9.6 Clarity Pharmaceuticals Competitive Strengths & Weaknesses
- 7.10 Curasight
 - 7.10.1 Curasight Details
 - 7.10.2 Curasight Major Business
 - 7.10.3 Curasight Targeted Radionuclide Therapy Product and Services
 - 7.10.4 Curasight Targeted Radionuclide Therapy Revenue, Gross Margin and Market

Share (2018-2023)

7.10.5 Curasight Recent Developments/Updates

7.10.6 Curasight Competitive Strengths & Weaknesses

7.11 Nordic Nanovector

7.11.1 Nordic Nanovector Details

7.11.2 Nordic Nanovector Major Business

7.11.3 Nordic Nanovector Targeted Radionuclide Therapy Product and Services

7.11.4 Nordic Nanovector Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)

7.11.5 Nordic Nanovector Recent Developments/Updates

7.11.6 Nordic Nanovector Competitive Strengths & Weaknesses

7.12 Philogen

7.12.1 Philogen Details

7.12.2 Philogen Major Business

7.12.3 Philogen Targeted Radionuclide Therapy Product and Services

7.12.4 Philogen Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)

7.12.5 Philogen Recent Developments/Updates

7.12.6 Philogen Competitive Strengths & Weaknesses

7.13 RadioMedix

7.13.1 RadioMedix Details

7.13.2 RadioMedix Major Business

7.13.3 RadioMedix Targeted Radionuclide Therapy Product and Services

7.13.4 RadioMedix Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)

7.13.5 RadioMedix Recent Developments/Updates

7.13.6 RadioMedix Competitive Strengths & Weaknesses

7.14 Telix Pharmaceuticals

7.14.1 Telix Pharmaceuticals Details

7.14.2 Telix Pharmaceuticals Major Business

7.14.3 Telix Pharmaceuticals Targeted Radionuclide Therapy Product and Services

7.14.4 Telix Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)

7.14.5 Telix Pharmaceuticals Recent Developments/Updates

7.14.6 Telix Pharmaceuticals Competitive Strengths & Weaknesses

7.15 Orano Med

7.15.1 Orano Med Details

7.15.2 Orano Med Major Business

7.15.3 Orano Med Targeted Radionuclide Therapy Product and Services

- 7.15.4 Orano Med Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
- 7.15.5 Orano Med Recent Developments/Updates
- 7.15.6 Orano Med Competitive Strengths & Weaknesses
- 7.16 Actinium Pharmaceuticals
 - 7.16.1 Actinium Pharmaceuticals Details
 - 7.16.2 Actinium Pharmaceuticals Major Business
 - 7.16.3 Actinium Pharmaceuticals Targeted Radionuclide Therapy Product and Services
 - 7.16.4 Actinium Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
 - 7.16.5 Actinium Pharmaceuticals Recent Developments/Updates
 - 7.16.6 Actinium Pharmaceuticals Competitive Strengths & Weaknesses
- 7.17 Y-mAbs Therapeutics
 - 7.17.1 Y-mAbs Therapeutics Details
 - 7.17.2 Y-mAbs Therapeutics Major Business
 - 7.17.3 Y-mAbs Therapeutics Targeted Radionuclide Therapy Product and Services
 - 7.17.4 Y-mAbs Therapeutics Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
 - 7.17.5 Y-mAbs Therapeutics Recent Developments/Updates
 - 7.17.6 Y-mAbs Therapeutics Competitive Strengths & Weaknesses
- 7.18 Fusion Pharmaceuticals
 - 7.18.1 Fusion Pharmaceuticals Details
 - 7.18.2 Fusion Pharmaceuticals Major Business
 - 7.18.3 Fusion Pharmaceuticals Targeted Radionuclide Therapy Product and Services
 - 7.18.4 Fusion Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
 - 7.18.5 Fusion Pharmaceuticals Recent Developments/Updates
 - 7.18.6 Fusion Pharmaceuticals Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

- 8.1 Targeted Radionuclide Therapy Industry Chain
- 8.2 Targeted Radionuclide Therapy Upstream Analysis
- 8.3 Targeted Radionuclide Therapy Midstream Analysis
- 8.4 Targeted Radionuclide Therapy Downstream Analysis

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

10.1 Methodology

10.2 Research Process and Data Source

10.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Targeted Radionuclide Therapy Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Table 2. World Targeted Radionuclide Therapy Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)

Table 3. World Targeted Radionuclide Therapy Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)

Table 4. World Targeted Radionuclide Therapy Revenue Market Share by Region (2018-2023), (by Headquarter Location)

Table 5. World Targeted Radionuclide Therapy Revenue Market Share by Region (2024-2029), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Targeted Radionuclide Therapy Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)

Table 8. World Targeted Radionuclide Therapy Consumption Value by Region (2018-2023) & (USD Million)

Table 9. World Targeted Radionuclide Therapy Consumption Value Forecast by Region (2024-2029) & (USD Million)

Table 10. World Targeted Radionuclide Therapy Revenue by Player (2018-2023) & (USD Million)

Table 11. Revenue Market Share of Key Targeted Radionuclide Therapy Players in 2022

Table 12. World Targeted Radionuclide Therapy Industry Rank of Major Player, Based on Revenue in 2022

Table 13. Global Targeted Radionuclide Therapy Company Evaluation Quadrant

Table 14. Head Office of Key Targeted Radionuclide Therapy Player

Table 15. Targeted Radionuclide Therapy Market: Company Product Type Footprint

Table 16. Targeted Radionuclide Therapy Market: Company Product Application Footprint

Table 17. Targeted Radionuclide Therapy Mergers & Acquisitions Activity

Table 18. United States VS China Targeted Radionuclide Therapy Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 19. United States VS China Targeted Radionuclide Therapy Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 20. United States Based Targeted Radionuclide Therapy Companies, Headquarters (States, Country)

Table 21. United States Based Companies Targeted Radionuclide Therapy Revenue, (2018-2023) & (USD Million)

Table 22. United States Based Companies Targeted Radionuclide Therapy Revenue Market Share (2018-2023)

Table 23. China Based Targeted Radionuclide Therapy Companies, Headquarters (Province, Country)

Table 24. China Based Companies Targeted Radionuclide Therapy Revenue, (2018-2023) & (USD Million)

Table 25. China Based Companies Targeted Radionuclide Therapy Revenue Market Share (2018-2023)

Table 26. Rest of World Based Targeted Radionuclide Therapy Companies, Headquarters (States, Country)

Table 27. Rest of World Based Companies Targeted Radionuclide Therapy Revenue, (2018-2023) & (USD Million)

Table 28. Rest of World Based Companies Targeted Radionuclide Therapy Revenue Market Share (2018-2023)

Table 29. World Targeted Radionuclide Therapy Market Size by Type, (USD Million), 2018 & 2022 & 2029

Table 30. World Targeted Radionuclide Therapy Market Size by Type (2018-2023) & (USD Million)

Table 31. World Targeted Radionuclide Therapy Market Size by Type (2024-2029) & (USD Million)

Table 32. World Targeted Radionuclide Therapy Market Size by Application, (USD Million), 2018 & 2022 & 2029

Table 33. World Targeted Radionuclide Therapy Market Size by Application (2018-2023) & (USD Million)

Table 34. World Targeted Radionuclide Therapy Market Size by Application (2024-2029) & (USD Million)

Table 35. Bayer Basic Information, Area Served and Competitors

Table 36. Bayer Major Business

Table 37. Bayer Targeted Radionuclide Therapy Product and Services

Table 38. Bayer Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 39. Bayer Recent Developments/Updates

Table 40. Bayer Competitive Strengths & Weaknesses

Table 41. Novartis Basic Information, Area Served and Competitors

Table 42. Novartis Major Business

Table 43. Novartis Targeted Radionuclide Therapy Product and Services

Table 44. Novartis Targeted Radionuclide Therapy Revenue, Gross Margin and Market

Share (2018-2023) & (USD Million)

Table 45. Novartis Recent Developments/Updates

Table 46. Novartis Competitive Strengths & Weaknesses

Table 47. Lantheus Basic Information, Area Served and Competitors

Table 48. Lantheus Major Business

Table 49. Lantheus Targeted Radionuclide Therapy Product and Services

Table 50. Lantheus Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 51. Lantheus Recent Developments/Updates

Table 52. Lantheus Competitive Strengths & Weaknesses

Table 53. Aurobindo Pharma Basic Information, Area Served and Competitors

Table 54. Aurobindo Pharma Major Business

Table 55. Aurobindo Pharma Targeted Radionuclide Therapy Product and Services

Table 56. Aurobindo Pharma Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 57. Aurobindo Pharma Recent Developments/Updates

Table 58. Aurobindo Pharma Competitive Strengths & Weaknesses

Table 59. Mundipharma Basic Information, Area Served and Competitors

Table 60. Mundipharma Major Business

Table 61. Mundipharma Targeted Radionuclide Therapy Product and Services

Table 62. Mundipharma Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 63. Mundipharma Recent Developments/Updates

Table 64. Mundipharma Competitive Strengths & Weaknesses

Table 65. China Isotope & Radiation Basic Information, Area Served and Competitors

Table 66. China Isotope & Radiation Major Business

Table 67. China Isotope & Radiation Targeted Radionuclide Therapy Product and Services

Table 68. China Isotope & Radiation Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 69. China Isotope & Radiation Recent Developments/Updates

Table 70. China Isotope & Radiation Competitive Strengths & Weaknesses

Table 71. Curium Pharmaceuticals Basic Information, Area Served and Competitors

Table 72. Curium Pharmaceuticals Major Business

Table 73. Curium Pharmaceuticals Targeted Radionuclide Therapy Product and Services

Table 74. Curium Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 75. Curium Pharmaceuticals Recent Developments/Updates

- Table 76. Curium Pharmaceuticals Competitive Strengths & Weaknesses
- Table 77. Gilead Sciences Basic Information, Area Served and Competitors
- Table 78. Gilead Sciences Major Business
- Table 79. Gilead Sciences Targeted Radionuclide Therapy Product and Services
- Table 80. Gilead Sciences Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 81. Gilead Sciences Recent Developments/Updates
- Table 82. Gilead Sciences Competitive Strengths & Weaknesses
- Table 83. Clarity Pharmaceuticals Basic Information, Area Served and Competitors
- Table 84. Clarity Pharmaceuticals Major Business
- Table 85. Clarity Pharmaceuticals Targeted Radionuclide Therapy Product and Services
- Table 86. Clarity Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 87. Clarity Pharmaceuticals Recent Developments/Updates
- Table 88. Clarity Pharmaceuticals Competitive Strengths & Weaknesses
- Table 89. Curasight Basic Information, Area Served and Competitors
- Table 90. Curasight Major Business
- Table 91. Curasight Targeted Radionuclide Therapy Product and Services
- Table 92. Curasight Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 93. Curasight Recent Developments/Updates
- Table 94. Curasight Competitive Strengths & Weaknesses
- Table 95. Nordic Nanovector Basic Information, Area Served and Competitors
- Table 96. Nordic Nanovector Major Business
- Table 97. Nordic Nanovector Targeted Radionuclide Therapy Product and Services
- Table 98. Nordic Nanovector Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 99. Nordic Nanovector Recent Developments/Updates
- Table 100. Nordic Nanovector Competitive Strengths & Weaknesses
- Table 101. Philogen Basic Information, Area Served and Competitors
- Table 102. Philogen Major Business
- Table 103. Philogen Targeted Radionuclide Therapy Product and Services
- Table 104. Philogen Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 105. Philogen Recent Developments/Updates
- Table 106. Philogen Competitive Strengths & Weaknesses
- Table 107. RadioMedix Basic Information, Area Served and Competitors
- Table 108. RadioMedix Major Business

- Table 109. RadioMedix Targeted Radionuclide Therapy Product and Services
- Table 110. RadioMedix Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 111. RadioMedix Recent Developments/Updates
- Table 112. RadioMedix Competitive Strengths & Weaknesses
- Table 113. Telix Pharmaceuticals Basic Information, Area Served and Competitors
- Table 114. Telix Pharmaceuticals Major Business
- Table 115. Telix Pharmaceuticals Targeted Radionuclide Therapy Product and Services
- Table 116. Telix Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 117. Telix Pharmaceuticals Recent Developments/Updates
- Table 118. Telix Pharmaceuticals Competitive Strengths & Weaknesses
- Table 119. Orano Med Basic Information, Area Served and Competitors
- Table 120. Orano Med Major Business
- Table 121. Orano Med Targeted Radionuclide Therapy Product and Services
- Table 122. Orano Med Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 123. Orano Med Recent Developments/Updates
- Table 124. Orano Med Competitive Strengths & Weaknesses
- Table 125. Actinium Pharmaceuticals Basic Information, Area Served and Competitors
- Table 126. Actinium Pharmaceuticals Major Business
- Table 127. Actinium Pharmaceuticals Targeted Radionuclide Therapy Product and Services
- Table 128. Actinium Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 129. Actinium Pharmaceuticals Recent Developments/Updates
- Table 130. Actinium Pharmaceuticals Competitive Strengths & Weaknesses
- Table 131. Y-mAbs Therapeutics Basic Information, Area Served and Competitors
- Table 132. Y-mAbs Therapeutics Major Business
- Table 133. Y-mAbs Therapeutics Targeted Radionuclide Therapy Product and Services
- Table 134. Y-mAbs Therapeutics Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 135. Y-mAbs Therapeutics Recent Developments/Updates
- Table 136. Fusion Pharmaceuticals Basic Information, Area Served and Competitors
- Table 137. Fusion Pharmaceuticals Major Business
- Table 138. Fusion Pharmaceuticals Targeted Radionuclide Therapy Product and Services
- Table 139. Fusion Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 140. Global Key Players of Targeted Radionuclide Therapy Upstream (Raw Materials)

Table 141. Targeted Radionuclide Therapy Typical Customers

List of Figure

Figure 1. Targeted Radionuclide Therapy Picture

Figure 2. World Targeted Radionuclide Therapy Total Market Size: 2018 & 2022 & 2029, (USD Million)

Figure 3. World Targeted Radionuclide Therapy Total Market Size (2018-2029) & (USD Million)

Figure 4. World Targeted Radionuclide Therapy Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)

Figure 5. World Targeted Radionuclide Therapy Revenue Market Share by Region (2018-2029), (by Headquarter Location)

Figure 6. United States Based Company Targeted Radionuclide Therapy Revenue (2018-2029) & (USD Million)

Figure 7. China Based Company Targeted Radionuclide Therapy Revenue (2018-2029) & (USD Million)

Figure 8. Europe Based Company Targeted Radionuclide Therapy Revenue (2018-2029) & (USD Million)

Figure 9. Japan Based Company Targeted Radionuclide Therapy Revenue (2018-2029) & (USD Million)

Figure 10. South Korea Based Company Targeted Radionuclide Therapy Revenue (2018-2029) & (USD Million)

Figure 11. ASEAN Based Company Targeted Radionuclide Therapy Revenue (2018-2029) & (USD Million)

Figure 12. India Based Company Targeted Radionuclide Therapy Revenue (2018-2029) & (USD Million)

Figure 13. Targeted Radionuclide Therapy Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)

Figure 16. World Targeted Radionuclide Therapy Consumption Value Market Share by Region (2018-2029)

Figure 17. United States Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)

Figure 18. China Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)

Figure 20. Japan Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)

Figure 23. India Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of Targeted Radionuclide Therapy by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for Targeted Radionuclide Therapy Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Targeted Radionuclide Therapy Markets in 2022

Figure 27. United States VS China: Targeted Radionuclide Therapy Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Targeted Radionuclide Therapy Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Targeted Radionuclide Therapy Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Targeted Radionuclide Therapy Market Size Market Share by Type in 2022

Figure 31. Beta-emitting

Figure 32. Targeted Alpha Therapy

Figure 33. World Targeted Radionuclide Therapy Market Size Market Share by Type (2018-2029)

Figure 34. World Targeted Radionuclide Therapy Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 35. World Targeted Radionuclide Therapy Market Size Market Share by Application in 2022

Figure 36. Solid Tumor

Figure 37. Non Hodgkin Lymphoma

Figure 38. Targeted Radionuclide Therapy Industrial Chain

Figure 39. Methodology

Figure 40. Research Process and Data Source

I would like to order

Product name: Global Targeted Radionuclide Therapy Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/G559EDA6F8C6EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G559EDA6F8C6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970